Experts Anticipate Swift Return To Normal For Post-Shutdown FDA

Despite warnings from the medical device industry that FDA would be slammed by a backlog of medical product applications that piled up during the shutdown, a former FDA advisory told Inside Health Policy the agency’s user fee-funded activities should return to normal operations and workload shortly. One lawyer agrees with that assertion but adds that agency activities not funded with user fees will more than likely be off to a sluggish start, since those activities had no funding during...